Chiesi Ventures
Investment Type: Venture Capital
Investment Stage: Series A
Portfolio 8
| Date | Name | Website | Total Raised | Location |
| 16.11.2016 | Glycomine ... | glycomine.com | $228M | United Sta... |
| - | SentienBio... | sentienbiotech.com | $12M | United Sta... |
| - | Minoryx Th... | minoryx.com | $106.01M | Spain, Cat... |
| - | VelosBio | velosbio.com | $195M | United Sta... |
| - | Aura Biosc... | aurabiosciences.com | $183M | United Sta... |
| - | 4D Molecul... | 4dmoleculartherapeutics.com | $165M | United Sta... |
| - | CuraSen | curaseninc.com | $54.5M | - |
| - | Kezar Life... | kezarlifesciences.com | $50M | United Sta... |
Mentions in press and media 9
| Date | Title | Description |
| 23.10.2023 | Which VCs are investing in rare diseases? | Firms include Chiesi Ventures, Frazier Healthcare Partners, OrbiMed, and Atlas Venture In the United States alone 25 million people suffer from rare disease, a number that jumps to 400 million people globally. While 1 in 10 people will suff... |
| 02.04.2019 | Aura Biosciences cierra una ronda Serie D de $40M liderada por Medicxi, acuden Ysios, Advent Life, Aris Bioscience, Chiesi, ColumbusVP y Lundbeckfonden | 02/04/2019 Nota de prensa AURA BIOSCIENCES CIERRA UNA RONDA SERIE D DE $40 MILLONES LIDERADA POR MEDICXI, ACUDEN YSIOS CAPITAL, ADVENT LIFE SCIENCES, ARIS BIOSCIENCE, CHIESI, COLUMBUSVP Y LUNDBECKFONDEN. Aura Biosciences, a leader in the... |
| 26.11.2016 | Chiesi Ventures Joins $12M Series A for Glycomine | Glycomine, Inc. a biotechnology company developing a new generation of replacement therapies for rare diseases, announced that it has raised $12 million in a Series A financing led by Sanderling Ventures and supported by Chiesi Ventures as ... |
| 16.11.2016 | Rare disease biotech Glycomine raises $12M, with help from Chiesi venture arm | In its Series A announced today Glycomine, an early-stage biotech working on replacement therapies for rare diseases, raised $12 million with help from Sanderling Ventures and Chiesi Ventures. The round also saw money injected from “existin... |
| 30.09.2016 | Aura Biosciences, participada por Ysios Capital, cierra una ronda de $8 millones | 30/09/2016 AURA BIOSCIENCIES, PARTICIPADA POR YSIOS CAPITAL, CIERRA UNA RONDA DE $8 MILLONES. Aura Biosciences, compañía biotecnológica participada por la entidad de capital riesgo (venture capital) Ysios Capital, ha anunciado el cierre d... |
| 14.10.2015 | Minoryx Therapeutics cierra una ronda de €19,4M liderada por Ysios. Acuden CaixaCR, Kurma, Roche VF, Idinvest, Chiesi y Health Equity | 14/10/2015 MINORYX THERAPEUTICS CIERRA UNA RONDA DE €19,4 MILLONES LIDERADA POR YSIOS CAPITAL. ACUDEN CAIXA CAPITAL RISC, KURMA PARTNERS, ROCHE VENTURE FUND, IDINVEST, CHIESI VENTURES Y HEALTH EQUITY. Minoryx Therapeutics, una compañía es... |
| 14.10.2015 | Minoryx Therapeutics completes Series A funding of €19.4M ($21.7M) | Minoryx Therapeutics, a drug development company specialized in the discovery of new drugs for orphan diseases, today announces it has completed a Series A funding round of €19.4M ($21.7M). Ysios Capital, a Spanish investment fund, led the ... |
| 09.10.2015 | Daily funding roundup - October 14, 2015 | Area 1 Security raised $15M eMMs, Inc. secured over $2 million in company's Series-A round of funding from private South African individual investor to build the cyber data protection fortress, FortKnoxx. Patent pending, FortKnoxx Fortress ... |
| 02.09.2014 | Chiesi Group Creates Corporate Venture Capital Fund | The Chiesi Group, a Parma, Italy-based research-focused international group which researches, develops and commercializes pharmaceutical solutions in the respiratory therapeutics and specialist medicine areas, has created its corporate vent... |